All News

RA,Rx,puzzle

Maximizing DMARDs to Strive for Steroid-Free Remission in RA

Jiha Lee, MD

In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).

Read Article
guidelines.recommendations.jpg

Is Your Practice Up to Date? New Guidelines for SLE Nephritis

Michael Putman, MD, MSCI

Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.

Read Article
search bar

ICYMI: How Online Searches Reveal Patient Needs

Bella Mehta, MBBS, MS

Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and treatment-related searches for rheumatic conditions.

Read Article
Best of

#ACR Best 2024 - Day 4

Jack Cush, MD

Although the last day of ACR Convergence 2024 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today.  As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.

Read Article
maze-1804499_1280.jpg

Methotrexate to Prevent RA, Clear as Mud

Richard Conway, MBBChBAO, PhD

Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk ACPA- patients.

Read Article
artificial intelligence machine learning computer

Predicting flares in rheumatic diseases with machine learning

Antoni Chan, MD, PhD

Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.

Read Article
Prgnancy,outcome

Improving fertility in women with RA

Jiha Lee, MD

For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way for improved outcomes.

Read Article
Changing Mindsets about Methotrexate Side Effects Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24. https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr

Links:

Dr. John Cush RheumNow ( View Tweet)
Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/x662FbdNoR https://t.co/uvMPHpmRHZ

Links:

Dr. John Cush RheumNow ( View Tweet)
🌟IgG4RD: Lessons from the first 20 years🌟by Prof John Stone ⭐️Lesson 1- IgG4RD is a variable vessel vasculitis ✨Can cause small vessel vasculitis of the skin ✨One of few vasculitis causing coronary arteritis in adults ⭐️Lesson 2- IgG4RD is more common and severe in males… https://t.co/PvFXyOl5bp https://t.co/hAMelBoZvB

Links:

Darpan Thakare darpan06T ( View Tweet)
Aging Gracefully in Managing Rheumatic Diseases Dr. Mrinalini Dey and Dr. Elena Myasoedova review highlights from a session on aging presented at #ACR24. https://t.co/tyT5d0JsEG https://t.co/szfDsSuWBx

Links:

Dr. John Cush RheumNow ( View Tweet)
Up-front Secukinumab in PsA? We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the… https://t.co/OAQOutluPe https://t.co/gLfG840DBP
Dr. John Cush RheumNow ( View Tweet)
Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq

Links:

Dr. John Cush RheumNow ( View Tweet)
Time the💉 Response to pneumococcal vaccine better when given before starting MTX. Stay updated on ACR and EULAR vaccination recommendations! #ACR24 @RheumNow ABST#2676

Jiha Lee JihaRheum ( View Tweet)

Hypoxia seems to exacerbate neutrophil activation by ANCA - enhanced F-Actin polymerization - enhanced NET formation Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns? @RheumNow #ACR24 https://t.co/KxaeMvkd2t

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Increased risk of mortality related to negative effects of GC use persists long after stopping and never return to pre-GC levels. #GCStewardship #ACR24 @RheumNow ABST#2673 https://t.co/5AwHDmvQGf

Links:

Jiha Lee JihaRheum ( View Tweet)
Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx

Links:

Janet Pope Janetbirdope ( View Tweet)
In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or Ab levels in Anifrolumab-treated pts. AEs - mild, moderate No serious aEs 💉#vaccinate your pts on anifrolumab with influenza @RheumNow #ACR24 abs2424 https://t.co/XPwlzUS02i

Links:

sheila RHEUMarampa ( View Tweet)
Hydralazine - known culprit of drug-induced AAV How does hydral (H) AAV differ from primary (1) AAV? 💥 High dual positivity MPO/PR3 💥 DAH / pleuritis more common in H-AAV 💥 ENT, constitutional, nervous, ILD in 1-AAV 💥 More 6mo remission in H-AAV @rheumnow #ACR24 Abst 2496

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr

Links:

Richard Conway RichardPAConway ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×